Caner Saygin to Leukemia, Myeloid, Acute
This is a "connection" page, showing publications Caner Saygin has written about Leukemia, Myeloid, Acute.
Connection Strength
1.962
-
Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq. Leukemia. 2021 12; 35(12):3406-3420.
Score: 0.485
-
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Am J Hematol. 2020 12; 95(12):1457-1465.
Score: 0.463
-
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. Blood Cancer J. 2018 01 10; 8(1):4.
Score: 0.384
-
Emerging therapies for acute myeloid leukemia. J Hematol Oncol. 2017 04 18; 10(1):93.
Score: 0.365
-
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 Apr; 204(4):1238-1242.
Score: 0.145
-
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia. Blood Cancer J. 2021 03 03; 11(3):48.
Score: 0.119